Rollins Inc (NYSE: ROL), the Atlanta-based global pest control operator whose brands include Orkin and HomeTeam Pest Defense, is due to report its first-quarter 2026 results after market close on April 22, with analysts expecting adjusted earnings per share of $0.24, a 9.1 percent increase from $0.22 in the same quarter last year, and revenue around $945 million as the company attempts to restore confidence following a rare earnings miss in its Q4 2025 print.
The fourth-quarter result, reported in February, delivered adjusted EPS of $0.25 against a consensus of $0.27 and revenue of $912.9 million against an estimate of $925 million, a modest shortfall that nonetheless prompted a downgrade from Wells Fargo to Equal Weight and a revision to near-term estimates that left the stock around 18 percent below its 52-week high heading into the current quarter.
Rollins has an unusual track record for a mid-cap services company: 24 consecutive years of revenue growth through the end of 2025, driven by a Business model built around recurring subscription-style pest control contracts, geographic expansion through acquisitions and organic market penetration in both residential and commercial verticals. The company’s gross margin of approximately 52.8 percent reflects the high-value nature of the service and the defensive characteristics of the category, where pest control expenditure tends to be maintained even during periods of consumer caution.
The Q1 print will be closely scrutinised for any signs that the Q4 miss reflected a genuine structural slowdown rather than seasonal or execution-related noise. Management guided for 7 to 8 percent organic revenue growth for 2026 at the time of the February call, a target that analysts broadly regard as achievable but which leaves no room for further shortfalls if the Wells Fargo downgrade thesis — that growth was decelerating — is to be rebutted.
The 22 analysts covering the stock maintain an average price target of $64.42, implying upside of approximately 18 percent from Monday’s trading around $54, with most framing the Q4 miss as an entry opportunity in a durable compounder rather than an indication of structural deterioration. First-quarter results should provide the first meaningful evidence of which interpretation is correct.